Video

Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer

Author(s):

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.

The trial included 530 randomized patients, half that received standard chemotherapy, which is FOLFOX6 with or without bevacizumab. The other half received Y-90 SIRT, which was given after the first or second administration of FOLFOX6 with or without bevacizumab. This treatment is for the palliative patient, said Arnold.

The results were surprising, said Arnold. There was no improvement in progression-free survival when all patients were taken into consideration. However, progression of the liver was significantly reduced with SIRT. This may be because many of the patients in the trial had disease in more than just the liver, which was not effected by the SIRT, said Arnold.

<<<

View more from the 2015 World GI Congress

Related Videos
Funda Meric-Bernstam, MD
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Neeta Somaiah, MD